CrossRoads Extremity Systems

CrossRoads Extremity Systems

CrossRoads Extremity Systems markets surgical correction products for bunions, primarily the miniBunion 3D system. The company claims its minimally invasive procedure, performed through a 1.5-inch incision, allows patients to walk immediately in a specialized postoperative shoe, versus 8-10 weeks in a cast for traditional bunion surgery. Its website targets both foot doctors and patients seeking a less invasive option. The firm focuses exclusively on foot deformity correction — bunions and, for severe cases, the dynaBunion 4D system. It positions itself against open-surgeon procedures such as the Chevron or Lapidus, which involve larger incisions and longer non-weight-bearing recovery. CrossRoads does not disclose investment stage, AUM, or number of surgeons who have adopted its system. Its operating model appears to rely on direct-to-surgeon marketing and patient referral. Based in Memphis, CrossRoads does not disclose team size, leadership, or any recent funding rounds, partnerships, or clinical studies. No public information exists regarding its ownership structure, financial performance, or any venture backing. The company does not list a professional network profile or named executives on its website. The absence of publicly available details on ownership, revenue, or clinical outcomes limits outside assessment. The firm may operate as a privately held medical device company without institutional investment, but no source confirms this.